Patent · US Active

Antibody binding nanofibrils

US11066452B2 · kind B2 · utility

0Cited by

0References

30Claims

0Family size

Inventors

Torleif Härd · Uppsala, SE
Mats Sandgren · Uppsala, SE
Benjamin Schmuck · Uppsala, SE

Key dates

Filing date	May 8, 2017
Grant date	Jul 20, 2021
Priority date	—
Expiry date	Nov 6, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present embodiments relate to antibody binding nanofibrils obtainable by co-fibrillation of carrier proteins and carrier-Z fusion proteins at a molar ratio selected within an interval of from 1:0.20 to 1:0.90. The antibody binding nanofibrils have extremely high antibody binding capacity and can thereby be used in various applications, such as antibody purification, and detection of biomarkers in point of care or laboratory diagnosis applications.(FIG. 6).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.